{
    "clinical_study": {
        "@rank": "56977", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Randomized 6 drug/2 placebo by group"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Randomized 6 drug/2 placebo by group"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Randomized 6 drug/2 placebo by group"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, tolerability and pharmacokinetics of\n      ABT-122 in subjects with Rheumatoid Arthritis."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose\n      study.  Twenty-four subjects with Rheumatoid Arthritis will be selected to participate.\n      Subjects will be randomized to receive either ABT-122 or placebo. ABT-122 or placebo will be\n      administered as subcutaneous (under the skin) injections in three dosing groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Rheumatoid Arthritis (RA) > 3 months.\n\n          -  On methotrexate (MTX) therapy => 3 months and on a stable dose for at least 4 weeks.\n\n          -  Except for MTX, must have discontinued all disease-modifying antirheumatic drugs\n             (DMARDs) for at least 3 months or 5 half-lives, whichever is longer.\n\n          -  Body Mass Index (BMI) is 19 to 38, inclusive.\n\n          -  Other than RA, subjects should be in good general health.\n\n        Exclusion Criteria:\n\n          -  Evidence of anti-ABT-122 antibody on a serum sample taken at Screening.\n\n          -  History of significant allergic reaction; or history of anaphylactic reaction to any\n             agent; or history of major reaction to any IgG containing product.\n\n          -  History of persistent chronic or active infection(s) requiring hospitalization or\n             treatment with intravenous or oral anti-microbials/antibiotics within the past 30\n             days.\n\n          -  History or evidence of active tuberculosis (TB) or the subject has evidence of risk\n             factor for latent TB.\n\n          -  Subject has any medical condition or illness other than RA that is not well\n             controlled with treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853033", 
            "org_study_id": "M14-048"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3"
                ], 
                "description": "Injection", 
                "intervention_name": "ABT-122", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3"
                ], 
                "description": "Placebo Injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Tolerability", 
            "Immunogenicity", 
            "Safety", 
            "Rheumatoid Arthritis", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lenexa", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66219"
                    }, 
                    "name": "Site Reference ID/Investigator# 108655"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Site Reference ID/Investigator# 107115"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Site Reference ID/Investigator# 118964"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Site Reference ID/Investigator# 100780"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Robert  Padley, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Collect all adverse events at each visit", 
                "measure": "Number of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From date of first dose of ABT-122 until 42 days after the last dose of ABT-122"
            }, 
            {
                "description": "Blood pressure, pulse and body temperature", 
                "measure": "Change in physical exam including vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "From date of first dose of ABT-122 until 42 days after last dose of ABT-122"
            }, 
            {
                "description": "Hematology, Chemistry, and Urinalysis", 
                "measure": "Change in clinical lab test results", 
                "safety_issue": "Yes", 
                "time_frame": "From date of first dose of ABT-122 until 42 days after the last dose of ABT-122"
            }, 
            {
                "description": "ECGs done in triplicate", 
                "measure": "Change in Electrocardiogram (ECG) results", 
                "safety_issue": "Yes", 
                "time_frame": "From subject's baseline (prior to subject's first dose) and up to 168 hours following the last dose of study drug"
            }, 
            {
                "description": "Cmax, Tmax, AUC, elimination rate constant and half-life", 
                "measure": "Determination of pharmacokinetic (PK) parameters", 
                "safety_issue": "No", 
                "time_frame": "Prior to first dose up to 42 days after the last dose of ABT-122"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853033"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measurement of ADA", 
            "measure": "Measurement of anti-drug anti-bodies (ADA) of ABT-122", 
            "safety_issue": "Yes", 
            "time_frame": "Prior to each dose and up until 42 days after the last dose of ABT-122"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}